prazosin

Trade name: minipress

Small moleculeapproved

Approved

Jun 23, 1976

Prazosin (trade names Minipress, Vasoflex, Lentopres, and Hypovase) is a selective α-1-adrenergic receptor antagonist used to treat hypertension. Prazosin acts by inhibiting the postsynaptic alpha-1-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation. Prazosin is orally active and has a minimal effect on cardiac function due to its alpha-1 receptor selectivity. However, when prazosin is started, heart rate and contractility go up in order to maintain the pre-treatment blood pressures because the body has reached homeostasis at its abnormally high blood pressure. The blood pressure lowering effect becomes apparent when prazosin is taken for longer periods of time. The heart rate and contractility go back down over time and blood pressure decreases. The antihypertensive characteristics of prazosin make it a second-line choice for the treatment of high blood pressure. Prazosin is also useful in treating urinary hesitancy associated with prostatic hyperplasia, blocking alpha-1 receptors, which control constriction of both the prostate and urethra. Although not a first line choice for either hypertension or prostatic hyperplasia, it is a choice for patients who present with both problems concomitantly. Common (4–10% frequency) side effects of prazosin include dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea. Less frequent (1–4%) side effects include vomiting, diarrhea, constipation, edema, orthostatic hypotension, dyspnea, syncope, vertigo, depression, nervousness, and rash. — NCATS

Clinical trial activity

65 trials · 59 clinical orgs · 17 marketing orgs

Phase 1
14
Phase 2
24
Phase 3
5
Phase 4
11

Earliest trial started Nov 1, 2000 (NCT00450164)

Timeline

1970s

  1. Jun 23, 1976

    Earliest FDA Approval

1980s

  1. Sep 12, 1988

    Teva — Marketing Organization

  2. Jan 11, 1989

    Watson Pharmaceuticals — Marketing Organization

  3. Feb 28, 1989

    Mylan — Marketing Organization

  4. Mar 15, 1989

    DAVA Pharmaceuticals — Marketing Organization

  5. Apr 10, 1989

    Ani Pharmaceuticals — Marketing Organization

  6. Apr 10, 1989

    IDT Australia Ltd. — Marketing Organization

2000s

  1. Jan 1, 2001

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Oct 3, 2018

    Novitium Pharma — Marketing Organization

2020s

  1. Dec 23, 2021

    Granules India — Marketing Organization

  2. Oct 21, 2022

    Appco Pharma — Marketing Organization

  3. Dec 30, 2022

    Mankind Pharma — Marketing Organization

  4. Mar 6, 2023

    Alembic — Marketing Organization

  5. Mar 31, 2023

    Aurobindo Pharma — Marketing Organization

  6. Jan 3, 2024

    Lannett Company, Inc. — Marketing Organization

  7. Sep 17, 2024

    MSN Laboratories — Marketing Organization

Indications

Mechanism of action

Combination products

Approval history

  • approvedPriority reviewJun 23, 1976

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC
Mol. weight
383.41 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
  • 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine
  • 2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
  • 2-(4-(2-furoyl)piperazin-1-yl)-4-amino-6,7-dimethoxyquinazoline
  • alphavase 0.5
  • alphavase 1
  • alphavase 2
  • alphavase 5
  • cp-12299
  • cp-12299
  • cp-122991
  • cp-122991
  • cp-12299-1
  • cp-12299-1
  • furazosin
  • hypovase
  • hypovase
  • hypovase b.d.
  • kentovace
  • minipress
  • minipress
  • minipress
  • minipress xl
  • minipress xl
  • prazosin
  • prazosin
  • prazosin
  • prazosin
  • prazosin
  • prazosin
  • prazosin
  • prazosin
  • prazosin
  • prazosin
  • prazosina
  • prazosina
  • prazosin clorhidrato
  • prazosine
  • prazosine
  • prazosine
  • prazosin hcl
  • prazosin hcl
  • prazosin hcl
  • prazosin hydrochloride
  • prazosin hydrochloride
  • prazosin hydrochloride
  • prazosin hydrochloride
  • prazosinum
  • prazosinum

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07231978Phase 1Nov 14, 2025Pfizer
NCT06629090Phase 2Jan 31, 2025University of Wisconsin
NCT06629077Phase 2Jan 31, 2025National Institute of Neurological Disorders and Stroke (NINDS), University of Wisconsin
NCT06147622Phase 1Feb 29, 2024Kinnov Therapeutics
NCT06287905Phase 4Feb 1, 2023Sohag University
NCT05189977Phase 1Aug 22, 2022IQVIA, Otsuka
NCT04967443Phase 1Sep 22, 2021Pfizer
NCT04793685Phase 1/Phase 2 (Phase 2)Jul 10, 2021Yale University
NCT04721353Phase 4Nov 9, 2020University of Washington
NCT04365257Phase 2May 13, 2020Fast Grants, Johns Hopkins University
NCT04108104Phase 2Oct 31, 2019ECSOR, Kinnov Therapeutics
NCT03997864Phase 4Jul 31, 2019University of Colorado, Denver
NCT03710642Phase 2Jul 30, 2019Department of Veteran Affairs, National Institute on Aging (NIA)
NCT04320589Phase 2Jun 30, 2019Cairo University, National Cancer Institute, Egypt
NCT03894345Phase 1May 24, 2019University of Manitoba
NCT03539614Phase 3Jun 4, 2018Department of Veteran Affairs
NCT03416569N/AMar 31, 2018University of Maryland
NCT03010995Phase 1May 15, 2017University of Louisville
NCT03045016Phase 2Feb 1, 2017University of Lyon
NCT03221751Phase 4Dec 1, 2016Department of Veteran Affairs
Showing 20 of 65 trials
Page 1 / 4

Organizations

Research & Development (59)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Department of Veteran AffairsGovernment19842001
University of WashingtonAcademic/Hospital131332001
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Government6032009
Department of DefenseGovernment4022004
Yale UniversityAcademic/Hospital4432009
National Institute on Aging (NIA)Government3122001
PfizerFor profit3212013
University of WisconsinAcademic/Hospital3312016
Augusta UniversityAcademic/Hospital2222014
Canadian Lung AssociationAcademic/Hospital2022012
Kinnov TherapeuticsFor profit2222019
National Institutes of Health (NIH)Government2022009
United States ArmyGovernment2022006
University of BordeauxAcademic/Hospital2122004
University of PittsburghAcademic/Hospital2212006
University of TorontoAcademic/Hospital2222012
A.R.C. K.E.M. Hospital Mumbai,Maharashtra,IndiaAcademic/Hospital1012006
Cairo UniversityAcademic/Hospital1012019
Cedars-Sinai Medical CenterAcademic/Hospital1112012
Cottage Hospital Mangaon, RaigadAcademic/Hospital1012006
59 organizations
Page 1 / 3

Marketing (20)

OrganizationOrg typeRelationshipDate
AlembicFor profitMKTGMar 6, 2023
Am TherapFor profitMKTG
Ani PharmaceuticalsFor profitMKTGApr 10, 1989
Ani PharmaceuticalsFor profitSYNApr 10, 1989
Appco PharmaFor profitMKTGOct 21, 2022
Aurobindo PharmaFor profitMKTGMar 31, 2023
DAVA PharmaceuticalsFor profitMKTGMar 15, 1989
Granules IndiaFor profitMKTGDec 23, 2021
IDT Australia Ltd.For profitMKTGApr 10, 1989
Lannett Company, Inc.For profitMKTGJan 3, 2024
MSN LaboratoriesFor profitMKTGSep 17, 2024
Mankind PharmaFor profitMKTGDec 30, 2022
MylanFor profitMKTGFeb 28, 1989
Novitium PharmaFor profitMKTGOct 3, 2018
PfizerFor profitNDA
PfizerFor profitSYNJun 23, 1976
Puracap PharmaceuticalFor profitMKTG
TevaFor profitMKTGSep 12, 1988
TevaFor profitSYNSep 12, 1988
Watson PharmaceuticalsFor profitMKTGJan 11, 1989